ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Last updated: October 5, 2015
Sponsor: Merck Sharp & Dohme Corp.
Overall Status: Completed

Phase

3

Condition

Throat And Tonsil Infections

Herpes Simplex Infections

Chickenpox (Varicella Zoster Infection)

Treatment

N/A

Clinical Study ID

NCT00975507
V221-009
2009_660
  • Ages 12-23
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • In good health

  • Negative clinical history of varicella, shingles, measles, mumps, and rubella

Exclusion

Exclusion Criteria:

  • Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone orin combination

  • Any immune impairment or deficiency

  • Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior tovaccination

  • Vaccination with an inactive vaccine with in the past 14 days

  • Vaccination with a live vaccine within the past 30 days

  • Immune globulin or any blood product administered in the past 3 months

Study Design

Total Participants: 480
Study Start date:
March 01, 1998
Estimated Completion Date:
June 30, 1999